Top

Reactions Weekly

Published in:

01-02-2024 | Lenvatinib | Case report

Carboplatin/lenvatinib/paclitaxel

Uterine clear cell carcinoma rebound and lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Chan JJ, et al. P64-2 Durable response and adverse events in a patient with non-MSI-H uterine clear cell carcinoma on pembrolizumab/lenvatinib. Annals of Oncology 34 (Suppl. 3): S1464 abstr. P64-2, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.annonc.2023.09.417 [abstract]

Title: Carboplatin/lenvatinib/paclitaxel
Uterine clear cell carcinoma rebound and lack of efficacy
Publication date: 01-02-2024
Publisher: Springer International Publishing
Keyword: Lenvatinib
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-53518-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Carboplatin/lenvatinib/paclitaxel

Uterine clear cell carcinoma rebound and lack of efficacy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Haloperidol/quetiapine

Aspirin/aluminium-glycinate

Obinutuzumab

Multiple drugs

AZD 1222/tozinameran

AZD-1222/Elasomeran/Tozinameran